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Context. Delirium often presents difficult management challenges in the
context of goals of care in palliative care settings.
Objectives. The aim was to formulate an analytical framework for further
research on delirium in palliative care settings, prioritize the associated research
questions, discuss the inherent methodological challenges associated with
relevant studies, and outline the next steps in a program of delirium research.
Methods. We combined multidisciplinary input from delirium researchers and
knowledge users at an international delirium study planning meeting, relevant
literature searches, focused input of epidemiologic expertise, and a meeting
participant and coauthor survey to formulate a conceptual research framework
and prioritize research questions.
Results. Our proposed framework incorporates three main groups of research
questions: the first was predominantly epidemiologic, such as delirium occurrence
rates, risk factor evaluation, screening, and diagnosis; the second covers pragmatic
management questions; and the third relates to the development of predictive
models for delirium outcomes. Based on aggregated survey responses to each
research question or domain, the combined modal ratings of ‘‘very’’ or
‘‘extremely’’ important confirmed their priority.
Conclusion. Using an analytical framework to represent the full clinical care
pathway of delirium in palliative care settings, we identified multiple knowledge
gaps in relation to the occurrence rates, assessment, management, and outcome
prediction of delirium in this population. The knowledge synthesis generated
from adequately powered, multicenter studies to answer the framework’s research
questions will inform decision making and policy development regarding
delirium detection and management and thus help to achieve better outcomes for
patients in palliative care settings. J Pain Symptom Manage 2014;48:159e175.
 2014 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc.
All rights reserved.Key Words
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assessment, treatment, predictive modelIntroduction
Delirium in Palliative Care: A Research
Priority
Delirium is one of the most common neuro-
psychiatric complications in patients who are
receiving palliative care. A recent epidemio-
logic review, based on a small number of
eligible studies conducted in inpatient pallia-
tive care units, reported a delirium prevalence
of 13%e88% and an incidence of 3%e45%,
where collectively 98.9% of the study samples
had a cancer diagnosis.1 These wide ranges
are likely due to variation across the included
studies in delirium diagnostic criteria, levels
of assessment, frequency of screening, and
proximity to death. Despite this high frequencyof delirium, it is remarkably underresearched
in the settings of palliative care.1e3 The paucity
of research may relate in part to the chal-
lenging and potentially elusive nature of
delirium in itself and also to complexities argu-
ably specific to palliative care.3e5 An awareness
of the contextual complexities of palliative care
and the settings in which it is delivered, as well
as determining the specific palliative care pop-
ulations to study, is a prerequisite for formu-
lating meaningful and patient-centered
research questions in investigating the inter-
face of delirium and palliative care.
Despite widening the definition of palliative
care to include ‘‘life threatening disease’’6 and
aside from some geographical and health-care
Vol. 48 No. 2 August 2014 161Conceptual Framework for Delirium Researchsystem exceptions, most patients in palliative
care settings have advanced cancer.7,8 The
growth in demand for palliative care in the
developed world over the past decade relates
to changing population demographics, such
as the increase in the proportion of elderly
persons,9,10 and the associated increase in
the number of cancer-related deaths in this
population.11,12 The expanded role of pallia-
tive care services is now reflected by the deliv-
ery of palliative care in multiple settings:
specialist inpatient units, including those in
stand-alone hospices and acute care settings;
hospital consult teams; and community pallia-
tive support teams.13e15 Collectively, given
the strength of advanced age and dementia
as risk factors for delirium;16 the propensity
for delirium to occur in the cancer trajectory,
especially in the advanced stages;1,17 and com-
bined with the projected population demo-
graphic changes in developed countries, it is
clear that delirium will have an increasingly
ubiquitous presence in the entire remit of
palliative care and thus constitutes a research
priority.
Clinical Trajectory of Delirium in Palliative
Care: A Case Vignette
Various agencies that commission or
conduct clinical research use an analytical
framework, typically based on clinical trajec-
tories, to strategically guide the development
process of generating research questions.18e20
To illustrate the complex clinical pathway of
delirium in palliative care, we present a hypo-
thetical though typical case vignette of a pa-
tient with advanced cancer, ‘‘Frank,’’ who
experiences two recognized episodes of
delirium during his eight months trajectory
with lung cancer (Table 1). This case high-
lights some of the contextual issues in pallia-
tive care relating to assessment, diagnosis,
management, impact, and outcome of
delirium.
Delirium Assessment and Diagnostic Issues
The clinical manifestations of delirium in
the palliative care population may vary widely
and thus present some unique diagnostic and
classification challenges.17,21 The Diagnostic
and Statistical Manual (DSM) of the American
Psychiatric Association has been the mainstay
in generating diagnostic criteria for delirium,and the 5th edition, DSM-5, has recently
been published (Table 2).22 Delirium is char-
acterized by an acute and fluctuating impair-
ment of attention and awareness, in addition
to other cognitive deficits such as perceptual
disturbances or memory impairment. Cogni-
tive impairment as part of a delirium or other
mild or major neurocognitive disorders is
highly prevalent in hospice and palliative
care settings and frequently missed.23,24 Tests
such as the Short Orientation and Memory
Concentration Test25 act as a crude screen
for cognitive impairment, regardless of its asso-
ciations, and in Frank’s case, the impairment
was associated with delirium. In addition to
cognitive deficits, the Confusion Assessment
Method (CAM)26 captured other features of
delirium in Frank’s case, such as acute onset
and fluctuating course.
Based on psychomotor status aberrations,
delirium is classified into hyperactive (hyper-
alert and often agitated), hypoactive (hypoa-
lert and often somnolent), or mixed
(features of both hypo- and hyperactive) sub-
types. In Frank’s case, he presented with the
mixed subtype; its features were associated
with a perceived need for an early visit to the
hospital emergency department. However,
the hypoactive subtype has been reported as
the most common in palliative care and is
also the subtype that is prone to misdiagnosis
as depression or fatigue in this setting.21 Fluc-
tuation in the intensity and nature of the clin-
ical manifestations of delirium, including
psychomotor hypoactivity, can result in missing
the diagnosis, and screening has therefore
been advocated in palliative care.1,27 However,
an optimal screening strategy for delirium in
palliative care settings that balances burden
and benefit has been neither evaluated nor
defined.
Delirium Management Issues
Episodes of delirium are invariably multifac-
torial in origin and typically involve acute
precipitating factorsdsuch as infection, hyper-
calcemia, and dehydrationdas in Frank’s first
episode of deliriumdsuperimposed on a back-
ground of baseline vulnerability, for example,
advanced age, advanced disease with multior-
gan dysfunction, or dementia.28e30 Although
the potential reversibility of delirium has
been demonstrated in many settings,29,31,32
Table 1
Case Vignette of Delirium in the Clinical Trajectory of Advanced Cancer
Context Description
Precancer Frank, a 72-year-old man, lived with his 70-year-old wife in a two-storey suburban
home. He was ambulatory and independent in activities of daily living. There
were no reported cognitive deficits.
Cancer diagnosis Eight months ago, he was diagnosed with nonesmall-cell (squamous cell) lung
cancer
Staging and management Locoregional, Stage III B. ECOG performance status ¼ 1. Despite a partial
response to initial concurrent chemoradiation, he became progressively
weaker, and his chemotherapy was discontinued three months ago.
1st episode of delirium  Two months ago
Presentation Brought to the hospital emergency room with acute-onset cognitive
impairment, behavioral disturbance, and two near falls in the preceding
48 hours.
Clinical history Dozing off during conversation, daytime sleepiness but awake and restless all
night, and at times appeared to have visual hallucinations. Vague complaints
of upper abdominal pain. Increasing respiratory distress over the preceding
two days.
Cognitive and behavioral assessment Scored 15/28 (normal <6) on Short Orientation and Memory Concentration
Test (SOMCT). Confusion Assessment Method (CAM) testing was positive for
delirium. Mixed hyperactive and hypoactive psychomotor features of
delirium were noted.
Decision-making and palliative care support Potential delirium treatment strategies were discussed with his wife as the
substitute decision maker. She initially did not want added investigational or
therapeutic burden on Frank because of intravenous lines or the possibility of
antibiotic side effects without some gain in his quality of life, yet she dearly
wished for more time for him. Ultimately, the consensus was to investigate
and treat his delirium.
Investigations Hypercalcemia noted. Consolidation, consistent with pneumonia on chest
imaging.
Treatment Delirium precipitant treatment: intravenous fluid, antibiotics, and zoledronic
acid. Symptomatic treatment of delirium: regularly scheduled and as needed
haloperidol.
Outcome Frank’s delirium largely reversed over three days. Cancer restaging revealed
hepatic and adrenal metastases (Stage IV) but no brain metastases. His
ECOG status had now deteriorated to three. He was discharged home under
the care of his family physician and the community palliative care team.
2nd episode of delirium  One month ago
Summary Despite worsening fatigue and episodic mild cognitive deficits, he remained at
home for four weeks before developing another episode of delirium. The
likelihood of recurrent hypercalcemia was discussed with his family, but as
their wish at this point was for solely comfort care without any further blood
work, this episode of delirium was not investigated. Because of family
exhaustion and concern about inadequate pain control, Frank was admitted
to a local inpatient hospice unit, where he received subcutaneous morphine
to control his pain and low-dose midazolam to control symptoms of delirium
before his death seven days later.
ECOG ¼ Eastern Cooperative Oncology Group.
162 Vol. 48 No. 2 August 2014Lawlor et al.including palliative care,29,30 though nonrever-
sal is clearly recognized as a frequent outcome
in the context of palliative care.29,33 The
reversibility of delirium in this patient popula-
tion, and the extent to which this can be pre-
dicted, is a major research priority.3 If
consistent with the agreed goals of care, the
standard approach in palliative care is to iden-
tify and treat modifiable precipitant
factors.17,34e36 As delirium frequently accom-
panies the terminal phase of illness in pallia-
tive care settings, there is a risk that some
potentially reversible episodes may beoverlooked or prematurely perceived as termi-
nal.3,17 Conversely, there is the risk that overly
aggressive medical interventions can be
applied in nonreversible episodes of delirium.
Thus, the reversibility of a particular episode
of delirium may present a clinical dilemma
for the clinician regarding how aggressively
to pursue reversal and has the potential for
substantive agonizing on the part of the substi-
tute decision makers, with the goals of care
often predicated on substantive uncertainty
about the potential for delirium reversal.
This decision-making challenge is also
Table 2
Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Diagnostic Criteria for Delirium
A. A disturbance in attention (i.e., reduced ability to direct, focus, sustain, and shift attention) and awareness (reduced
orientation to the environment).
B. The disturbance develops over a short period of time (usually hours to a few days), represents a change from baseline
attention and awareness, and tends to fluctuate in severity during the course of a day.
C. An additional disturbance in cognition (e.g., memory deficit, disorientation, language, visuospatial ability, or perception).
D. The disturbances in Criteria A and C are not better explained by another pre-existing, established, or evolving neurocognitive
disorder and do not occur in the context of a severely reduced level of arousal, such as coma.
E. There is evidence from the history, physical examination, or laboratory findings that the disturbance is a direct physiological
consequences of another medical condition, substance intoxication or withdrawal (i.e., due to a drug of abuse or a
medication), or exposure to a toxin, or is due to multiple etiologies
Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (2013). American Psychiatric Association. All
rights reserved.
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tute decision makers, such as Frank’s wife,
about the predicted benefit vs. burden of
investigation and consequent treatment of
identified delirium precipitants. Compara-
tively, in the case of Frank’s second episode
of delirium, his now known expressed wishes
to not have further investigations meant that
therapeutic decision making was clearer. Yet
an individualized approach is still warranted,
especially as treatment of his first delirium
episode gave him the opportunity to have a
month at home with his family.
Delirium Impact and Outcome Issues
Delirium is a distressing experience primar-
ily for the patient but also for the family.37e42
It impedes meaningful and highly valued
communication sometimes in a preciously nar-
row temporal window. Furthermore, delirium
may compromise the quality of pain and other
symptom assessments by health-care
personnel. Apart from the distressed decision
making during the first delirium episode,
other notable aspects of Frank’s case include
his symptomatic distress; his fall risk; reversal
of the first delirium episode with relatively
low burden interventions such as assisted hy-
dration, antibiotics, and bisphosphonate treat-
ment; family burden; and the major difficulty
in assessing pain in the context of delirium.
Objectives
The combined complexities of the delirium
syndrome and the palliative care context pose
significant challenges for the researcher, yet
for future improved patient and family out-
comes, it is imperative to address the gaps in
clinical research. Reflecting the trajectory is-
sues identified in our case vignette, theobjectives of this article are to 1) formulate
an analytical framework for further research
on delirium, based on a conventional clinical
approach in palliative care, 2) report a prelim-
inary level of priority to the research questions
arising from this analytical framework, 3)
discuss the inherent methodological chal-
lenges associated with studies designed to
answer the framework questions and propose
solutions, and 4) outline the next steps in
our program of research.Methods
We developed a provisional analytical frame-
work depicting the clinical care pathway of
delirium in palliative care. Grounded in deci-
sion theory, analytical frameworks are useful
in understanding the context and logic with
which clinical decisions are made or should
be made. Such frameworks are routinely used
in developing research questions or agenda,
so that once answered by evidence, decision
and policy makers are convinced of the
comparative effectiveness, harms, and cost-
effectiveness of alternative management op-
tions.18,19,43 Using an analytical framework to
articulate questions of research interest mini-
mizes investigator bias in the conception of
research, reveals previous beliefs and assump-
tions that are not evidence based, and imparts
patient-centered dimension to the research
and associated decision making.
As an integral part of the process in devel-
oping an analytical framework for delirium
research in the palliative care population, we
obtained multidisciplinary input from leading
delirium researchers, methodologists, primary
care and specialist-level clinicians, palliative
164 Vol. 48 No. 2 August 2014Lawlor et al.care experts, and clinical administrators at an
international two day delirium study planning
meeting in Ottawa, Canada, in June 2012.44
Our meeting was designed to promote collabo-
ration and initiate deliberations toward the
development of a research framework under
the broad heading of ‘‘Studies to Understand
Delirium In Palliative Settings’’ and hence the
acronym, SUNDIPS. Within this broad SUN-
DIPS program of research, we targeted three
major investigational domains for delirium in
palliative care settings as subprograms of
research: 1) epidemiologic issues and issues
of delirium prediction, screening, and diag-
nosis, 2) experiential or phenomenologic as-
pects of delirium in its entire trajectory,
including subsyndromal and full syndromal
states, and 3) comparative effectiveness of alter-
native management strategies in established
delirium. All presentations and interactions
during the sessional working groups were re-
corded and transcribed. The results of system-
atic literature searches in relation to the
subprograms of research are described in their
corresponding articles in this section.45e50
By integrating knowledge users and
engaging them in the consultative and collab-
orative process at this meeting, we aimed to
address the specific contextual sensitivities,
needs, and decisional determinants in pallia-
tive care and thus help to better inform the
rationale and design of future research, knowl-
edge translation, management guidelines, and
policy regarding delirium in this setting. The
data synthesis from this meeting and the asso-
ciated literature searches were supplemented
by subsequent focused input from coauthors
with recognized epidemiologic expertise.
Collectively, these inputs informed the formu-
lation of specific research questions at various
points in the analytical framework.
Having developed the research questions to
populate the research framework, themeeting at-
tendeesor coauthors (n¼ 30),with abackground
of delirium research and clinical experience in
palliative care, and those working with patients
with advanced cancer were asked to complete
an anonymous online pilot survey to assign a pre-
liminarypriority level (0¼N/A,not applicable or
unable to rate, 1 ¼ not at all important,
2¼ slightly important, 3¼moderately important,
4¼ very important, and5¼ extremely important)
to the research question or groups of questions.Five standard criteria were used to rate the impor-
tance of answering either an individual question
or at least one question in a domain, represented
by a predetermined group of related questions.51
The criteria were (A), need to determine the
burden and impact of disease in relation to
delirium; (B), need to informdecisions in clinical
practicewhere there is controversyoruncertainty;
(C), need to estimate the economic cost and/or
resource utilization associated with delirium;
(D) known need to address this knowledge
deficit; and (E) potential impact of the answer
on clinical practice. The need for ethics approval
for the survey was discussed with our local
research ethics board, but given that the raters
were either participants (n¼ 26) in the SUNDIPS
meetingwithaclearly informedobjectiveofdevel-
oping a research agenda or subsequently enlisted
as coauthors (n ¼ 4) for this purpose, formal
research ethics board application and approval
was deemed to be not necessary.
Finally, the reported methodological and
other challenges associated with the conduct
of studies in the research framework, their pro-
posed respective solutions, and an outline of
the next steps to advance the overall SUNDIPS
program of research were derived in part from
the SUNDIPS meeting and in part from subse-
quent focused input of epidemiologists and
other coauthors.Results and Discussion
Formulation of an Analytical Framework and
Pertinent Research Questions
The analytical framework developed by our
team for delirium research in palliative care set-
tings is presented in Figure 1. The individual
research questions populating the entire frame-
work are labeled Q1eQ18. These questions are
divided into three groups, each reflecting a ma-
jor domain with an associated overall research
goal or set of goals. We broadly discuss each
group, acknowledging that an in-depth discus-
sion of each specific question is beyond the
scope of this article. Questions cover a spectrum
of inquiries ranging from the prevalence of
delirium in various palliative care settings to
comparative test performance, their effective-
ness and harms, resource utilization, and incre-
mental costs when incorporated in patient
management strategies. The left half of the
Fig. 1. Analytical framework for research questions on delirium in palliative care settings. Boxes with broken lines
are not steps in the care pathway but describe either a relevant clinical equipoise or determinants of a pathway
step. zM1 and M2 are predelirium management strategies; M3 and M4 are strategies to manage established
delirium. ICER ¼ incremental cost-effectiveness ratio; QoL ¼ quality of life; PPV ¼ positive predictive value;
NPV ¼ negative predictive value; LR ¼ likelihood ratio; DoR ¼ diagnostic odds ratio; HR ¼ hazard ratio;
RR ¼ risk ratio; AUC ¼ area under the curve.
Vol. 48 No. 2 August 2014 165Conceptual Framework for Delirium Researchframework in Figure 1 depicts the care pathway
(and related questions) up to the onset of
delirium, whereas the right half displays the
pathway once delirium diagnosis is established.
Many of the questions arise at pivotal decision
points in the clinical care pathway where, in the
absence of evidence, there are substantive re-
ported differences in management,52 or where
clinical equipoise exists in relation to the choice
between alternative management options, for
example, outcomes based on the current stan-
dard management compared with those with
management directed by a risk prediction
model. We also prespecified a select number of
outcomes that are considered important for de-
cision making, including incremental cost-
effectiveness and resource utilization.
The first group of questions (Q1eQ9) is
presented in Table 3 and addresses the burden
of delirium in terms of its occurrence rates,
risk factor evaluation, screening, and diagnosisand is thus predominantly epidemiologic in
nature. Hosie et al.1 reported a systematic re-
view of delirium incidence and prevalence in
inpatient palliative care units; however, few
data exist to allow comparison across other
palliative care settings. Although risk factors
for delirium have been identified across a
wide variety of medical settings16,53 and the ef-
ficacy of some prevention strategies has been
clearly proven,54e56 data from palliative care
settings have been limited and thus far a single
prevention study with substantive recognized
methodological limitations failed to show
benefit.57 The negative outcome with this
study should not preclude future more rigor-
ously designed studies in the palliative care
population. Apart from psychoactive medica-
tions, the identification of risk factors in a
small number of studies, conducted in either
palliative or cancer care settings, has been
somewhat inconsistent.29,30,58e63
Table 3
Research Questions (Q1eQ9) of Analytical Framework for Delirium Research in Palliative Care Settings
Occurrence rates and burden of delirium
1. What are the incidences and prevalence rates of delirium in the various palliative care settings (acute care, inpatient hospice
and hospital care, and community palliative services)?
Delirium prediction
2. What are the baseline and precipitating risk factors for the onset of delirium?
3. Which is the most parsimonious delirium risk prediction model with the highest calibration and discrimination value under
the current standards of care?
4. Does the model have transportability or external validity?
5. What are the comparative effectiveness and harms of the high-performance risk prediction model(s) in reducing the
incidence of delirium and important delirium-associated outcomes? (i.e., what are the comparative effectiveness and harms of
delirium-preventative management strategies guided by risk prediction as opposed to the current standards of care?)
Screening for delirium
6. What is the test performance of cognitive active screening for delirium vs. nurse/informal caregiver observational passive
screening?
7. What are the comparative effectiveness and harms of cognitive active screening of all patients vs. cognitive active screening
triaged by nurse/informal caregiver observational passive screening for important delirium-associated outcomes?
Diagnosis of delirium
8. What are the comparative diagnostic performance and applicability limitations of the various validated delirium diagnostic
tools (in current use)?
9. What are the comparative effectiveness and harms of the various validated delirium diagnostic tools (in current use) for
important delirium-associated outcomes?
166 Vol. 48 No. 2 August 2014Lawlor et al.Can we develop a predictive model for inci-
dent delirium in palliative care? The purpose
of such a model would be to identify persons
at greatest risk of delirium. Pragmatically, the
question can be primarily focused in relation
to individuals at the point of admission to
inpatient or community palliative care services.
The basis of the model would be a prospective
observational cohort study examining baseline
and precipitating risk factors for incident
delirium. Apart from ‘‘subsyndromal’’ delirium
and other potential prodromal clinical predic-
tors,64,65 a prediction model might explore the
potential predictive role for biomarkers such
as cytokines, insulin-like growth factor-1,
cortisol, and C-reactive protein, though incon-
sistent findings have been noted to
date.61,66e70 Such studies will need careful
attention to how putative biomarkers other-
wise correlate with disease stage if their associ-
ations with delirium (over and above disease
stage) are to be understood. A fundamental
construct of predictive models in delirium is
the understanding that predisposing factors
(baseline risk) and precipitating factors
(illness severity) interact in a reciprocal
fashion.28,53 Accordingly, relatively minor
intercurrent illness can result in delirium in
older frail persons, whereas more severe acute
illness is necessary to produce delirium in
younger individuals. If such a model couldgenerate a risk prediction score in a manner
similar to the PRE-DELIRIC model for inten-
sive care units,71 it might be used to guide
early preventative interventions in delirium
and predict resource utilization. It could also
form the basis of power calculations in future
randomized controlled trials.
Although screening has been advocated in
palliative care settings, there are limited litera-
ture data on its evaluation.1 Also, there is little
evidence with which to compare the efficacy of
a cognitive screening tool requiring active pa-
tient participation, such as the Mini-Mental
State Examination72 or Short Orientation and
Memory Concentration Test, vs. a nurse-rated
observational tool, such as the Nursing
Delirium Screening Scale, though clearly the
latter is less burdensome in a vulnerable popu-
lation with advanced disease.45,73,74 A recent
study suggests that caregiver observations may
detect prodromal delirium features, especially
sleep disturbance, a finding that warrants
further evaluation.75 Also, use of the CAM by
family members (FAM-CAM) has demon-
strated high levels of sensitivity and speci-
ficity.76 Earlier diagnosis of delirium (M2 in
Fig. 1) could conceivably lead to earlier thera-
peutic intervention and thus potentially lessen
distress, whether the goals of care (Therapeu-
tic Strategy in Fig. 1) might be directed
toward either comfort and symptomatic
Vol. 48 No. 2 August 2014 167Conceptual Framework for Delirium Researchtreatment alone (Objective I in Fig. 1) or symp-
tomatic treatment in combination with treat-
ment of precipitant factors (Objective I in
Fig. 1). Although many assessment tools have
been developed and validated, apart from the
CAM,77 they have been exposed to limited vali-
dation in the palliative care population.45 Diag-
nostic challenges and outcome measures in
relation to subsyndromal delirium, delirium
superimposed on dementia, and the psycho-
motor subtypes are addressed separately.47
The second group of research questions
(Q10eQ14) is presented in Table 4; this group
largely covers pragmatic management questions,
especially in relation to differences across the
various palliative care settings, and would entail
longitudinal observational studies. A retrospec-
tive study of delirium documentation and man-
agement in hospice and hospital patients
referred to a palliative care team found that the
term ‘‘delirium’’ was used infrequently, but defin-
itive use of the term was associated with clearer
management plans in the hospital patients.27
The group also includes important questions
where clinical equipoise exists regarding both
pharmacologic and nonpharmacologic interven-
tions and ideally require a randomizedcontrolled
study trial design to answer the respective ques-
tions. Although comparative studies have been
reported regarding pharmacologic agents for
symptomatic control in other settings,48,78,79 few
have been conducted in palliative care
settings.48,80
The third group of questions (Q15eQ18) is
presented in Table 5; the questions relate to
the development of predictive models for
delirium outcomes in response to patient man-
agementdparticularly the outcome of
delirium reversibility. Accordingly, an exten-
sion of the delirium risk model (Q2eQ5)
would be to further investigate components
of delirium risk that might be reversible orTable 4
Research Questions (Q10eQ14) of Analytical Framework
Management of delirium
10. What is the extent of variability in management of delirium acr
and hospital care, and community palliative services)?
11. Is the variability in management of delirium across the various ca
and community palliative services) associated with important di
12. What are the comparative effectiveness and harms of delirium m
and/or substitute decision maker input vs. those that do not?
13. What are the comparative effectiveness and harms of the variou
14. What are the comparative effectiveness and harms of the varioumodifiable. The precipitating factors associ-
ated with delirium reversal in palliative care set-
tings have been examined in a small number of
studies.29,30,32,33,63 In a study examining
delirium reversibility, psychoactive medica-
tions, including opioids and benzodiazepines,
were independently associated with delirium
reversal, and both hypoxic encephalopathy
and nonrespiratory infection were indepen-
dently associated with nonreversal.29 Given
the paucity and inconsistent findings of litera-
ture data on risk evaluation and in turn the
limited data on reversibility predictors of
delirium in palliative care settings, there is a
compelling need for a prospective cohort
observational study for model development.
Unfortunately, because of the poor recognition
of delirium and its poor and inconsistent docu-
mentation in inpatient settings, research
studies to identify predictors through adminis-
trative databases are unlikely to be helpful.81
Furthermore, the external validity of delirium
reversibility findings in other care settings
such as intensive care is uncertain in relation
to palliative care settings.53
In summary, in palliative care settings, sub-
stantive evidence base deficits exist regarding
basic epidemiologic data, therapeutic strate-
gies, and their impact on the many outcome
measures of delirium, which poses uncertainty
for decision making in everyday clinical
practice. Similar to the priorities generally iden-
tified in relation to other settings,53,70,82 there is
therefore a compelling need for observational
cohort studies and randomized controlled trials
to address our proposed research questions in
palliative care and consequently inform a num-
ber of important outcomes:
 partial or complete reversibility of
delirium, and its sustainability, in
response to treatmentfor Delirium Research in Palliative Care Settings
oss the various care settings (acute care, inpatient hospice
re settings (acute care, inpatient hospice and hospital care,
fferences in outcomes of benefit and harms?
anagement strategies that incorporate advanced directives
s pharmacologic symptom-directed interventions?
s nonpharmacologic symptom-directed interventions?
Table 5
Research Questions (Q15eQ18) of Analytical Framework for Delirium Research in Palliative Care Settings
Prediction of response to management and treatment of delirium
15. In patients with established delirium, what are the risk factors that predict complete or partial reversibility of delirium and
sustainability of response?
16. Which is the most parsimonious risk prediction model with the highest calibration and discrimination value for predicting
complete or partial reversibility of delirium under the current standards of care?
17. Does the model have transportability or external validity?
18. What are the comparative effectiveness and harms of patient management guided by model(s) predicting delirium
reversibility vs. current standards of care?
168 Vol. 48 No. 2 August 2014Lawlor et al. symptomatic conservative management vs.
extensive workup to identify and treat
precipitating factors
 tailoring management objectives in light
of advanced directives or the agreed goals
of care
 cost and resource utilization measures
 risk factor evaluation and evaluation of
preventative strategies
 prediction of outcomes such as death;
falls; length of stay; patient, family mem-
ber, and health-care professional distress;
quality of life; pain relief; and impact on
family member bereavement.
Finally, although the experiential and phe-
nomenologic dimensions of delirium from
the patient, family, and health-care personnel
perspectives are largely embedded in the
outcome measures in Figure 1, their appar-
ently low level of prominence in the frame-
work is disproportionate to their actual
perceived level of importance in clinical prac-
tice. The inherent complexity associated with
these aspects warrants a mixed-methods
approach that embodies both qualitative and
quantitative methods.46Preliminary Priority Level of Research
Questions Based on Survey Results
The results of a survey of the SUNDIPS
meeting attendees and coauthors to assign
levels of importance to the research questions
are summarized in the bar chart in Figure 2.
Twenty-eight of 30 (93%) invited survey partic-
ipants responded. Rating the research do-
mains and their associated question(s)
according to the five criteria of importance
(AeE), the 28 survey respondents generated
an aggregate total of 140 ratings per domain
and an overall total of 840 ratings. Percentages
represent the number of categorical ratings
out of the total of 140 for each domain.Responding to the perceived importance of a
question or a domain in relation to a specific
criterion, ‘‘unable to rate or not applicable,’’
or ‘‘not at all important’’ occurred in only 18
(2%) and 22 (2.6%) of 840 ratings, respec-
tively. The modal response category was very
important for each of the domains, except
for Q8eQ9 and Q10eQ14, whose modal cate-
gories of response were moderately important
and extremely important, respectively. In sum-
mary, for each research domain or ques-
tion(s), a post hocecreated combination
category of either ‘‘very important’’ or
‘‘extremely important’’ represented the modal
response and ranged in frequency from 80.7%
for Q10eQ14 to 56.5% for Q6eQ7.
General Methodological Challenges of Studies
to Answer the Research Framework Questions
The challenges can be broadly categorized
as relating to the study population and setting,
the ascertainment of study outcomes and ex-
posures, and statistical issues in relation to lon-
gitudinal data analysis.
Study Population and Setting. There are many
general challenges in relation to conducting
any research in the palliative care population.
Patients in palliative care settings have
advanced disease, mostly advanced cancer,
and frequent comorbidities. Conducting
delirium research in the advanced cancer pop-
ulation or in any end-of-life condition is chal-
lenging because of patient vulnerability,
ethical issues around informed consent, and
willingness of patients to participate in
research, often resulting in limited patient
accrual to studies and high attrition rates in
those who are recruited.3e5 The ethical chal-
lenges and possible solutions are discussed
separately in this section.50 The recruitment
and attrition issues are challenging for most
centers, making multicenter collaboration
Fig. 2. Aggregate results of importance survey on research questions (Q1eQ18) from the analytical framework.
Each of the six question (Q) domains was rated according to five criteria of importance (AeE) by 28 survey par-
ticipants to give an aggregate total of 140 ratings per domain. Percentages represent the number of categorical
ratings out of the total of 140 for each domain.
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conduct adequately powered studies.83,84 In
turn, this necessitates agreement on common-
ality of assessment tools and procedures across
sites, including eligibility criteria. To broadly
represent the palliative care population, there
is an ethical and equity-based argument for an
inclusive approach that would include a
growing proportion with nonmalignant end-
of-life illnesses. However, the consequent het-
erogeneity creates challenges for statistical
analysis, especially in relation to predictive
models, whereas the homogeneity associated
with an exclusive selection of a cancer diag-
nosis for eligibility supports a more powerful
analysis. Larger sample sizes would allow strat-
ification in relation to malignant and nonma-
lignant diagnoses and also in relation to the
presence or absence of pre-existing dementia.
With an initial aim to generate robust pre-
dictive models, the study population of pri-
mary interest will most likely be defined as
persons with a cancer diagnosis, at least
initially. Given the desirability of ease of access
to investigative procedures, the predominant
care setting for recruitment will likely be an
inpatient palliative care unit, such as a hospice
or hospital-based unit. Combining sites torecruit such a population will encounter het-
erogeneity issues, including varying criteria
for admission to inpatient palliative care units,
variation in disease staging and performance
status, variation in the agreed goals of care,
and site availability of investigative proce-
dures, cancer treatments, and other services,
for example, psychiatry or palliative care
consultation. Accordingly, the multiple con-
structs contributing to heterogeneity will
need to be meaningfully and rigorously
defined and the consequent stratifications
accounted for in the analyses. Some
community-based palliative care teams have
sufficient access to laboratory services to allow
basic delirium investigation, and combining
this with emergency room data and standard-
ized caregiver reporting, may possibly be the
only way of optimally capturing data on
delirium in the community setting.
Ascertainment of Outcomes and Exposures. The
primary reference standard used in delirium
research is the DSM criteria, recently published
as the 5th edition, DSM-5 (Table 1).22 As with
many syndromes in psychiatric epidemiology,
the boundaries of the diagnosis are difficult to
define consistently across assessors and across
170 Vol. 48 No. 2 August 2014Lawlor et al.sites.85 Moreover, if an instrument is used for
screening and/or case ascertainment, multiple
sources for the propagation of misclassification
biases result in substantial losses of statistical po-
wer. Standardized procedures such as a semi-
structured interview to operationalize the
DSM-5 diagnostic criteria are necessary.
There is a trade-off between intensity of assess-
ment schedules (and necessary expertise) for
study personnel and the ability to assess large
numbers of participants. At one extreme, assess-
ment and diagnosis might be performed at the
same time, for example, using the gold standard
of a psychiatrist interview. This has the advantage
of expert case ascertainment at each assessment
but is potentially resource intensive. Alterna-
tively, a two-stage approach might involve a
screening test done more frequently by
personnelwith less expertise,with ascertainment
performed in screen positives by an experienced
palliative care practitioner. At each stage, it
would be essential to assess a random sample of
screen negatives. Consequently, targeted use of
expert ascertainment would be more efficient,
but the separation of the screening and ascer-
tainment processesmay be a problem given tem-
poral fluctuations in delirium. Clearly, the study
protocol should stipulate an optimal gap be-
tween screen and ascertainment. It would be
ideal to choose screening instruments or struc-
turedassessmentprotocolswithestablisheddiag-
nostic properties (sensitivity and specificity) and
thus validated in palliative care settings. The
lead-in to any epidemiologic study should
include an assessment of diagnostic accuracy of
the instruments within the study. Ethically, the
burden of assessment procedures, as reflected
by their duration and/or intensiveness and
consequent acceptability to participants, must
be considered.50 Inability to rate specific items
in severity-measuring tools may require prorat-
ing of the total score based on those items that
were rateable.86 The contribution by informants
(relatives and nurses) to the diagnosis of
delirium is clearly helpful and some assessment
tools have this capacity, though it may become
difficult to standardize as quality and quantity
of informant informationmay vary.More specific
recommendations regarding assessment tools
are made separately in this section.45
Any multicenter study will require careful
monitoring and a quality assurance program
to optimize interrater reliability.83 Ongoingsupport throughout the study is necessary,
though some of this could be Web or telecon-
ference based. In-person training is also essen-
tial, involving supervised assessments at
regular intervals throughout the study.
The same issues for case ascertainment are
relevant to the measurement and standard defi-
nition of predisposing and precipitating factors,
albeit with less impact on statistical power.
Although predisposing and precipitating fac-
tors may converge in the terminal trajectory,
pre-existing cognitive impairment is such a
strong risk factor for delirium that this key var-
iable must be incorporated in the initial clinical
assessment. Again, the issue of trade-off be-
tween burden and comprehensiveness from a
psychometric perspective arises in relation to a
baseline measure of cognitive function. The
choice of what biomarker(s) to evaluate as a
predictor of delirium risk or reversibility is a
controversial one. Based on its demonstrated
prognostic potential as an index of inflamma-
tion in patients with advanced cancer, C-reactive
protein should be considered in this regard.87
Longitudinal Assessments in Delirium. Serial
measurements are essential in delirium
because of its fluctuating nature and serve to
improve case ascertainment. It is also particu-
larly important to generate data toward a pre-
dictor model of reversibility. Longitudinal
analyses are more powerful as intraindividual
change (over time) can be separately modeled
from interindividual change (performance in
relation to the rest of the group). However,
the observational nature of longitudinal
delirium studies precludes drawing a direct
cause-effect conclusion. One of the biggest
challenges with longitudinal assessments in
the palliative care population is attrition, due
to either death or subjects’ inability to partici-
pate in assessments as their disease advances.
To properly account for the fluctuating nature
of the syndrome, variable length of each
episode, time between episodes, missing data,
censored follow-up, and repeated measures
of changing patient characteristics over the
course of care, appropriate statistical analytical
plans are a necessity. Longitudinal statistical
approaches have been comprehensively re-
viewed by Adamis.88 While the analytical
framework should be tied to the particular
needs of the research objectives, special
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methods, such as generalized estimating equa-
tions and mixed-effects models, for predictor
and risk factor evaluation. Moreover, if time
is under investigation, special models of sur-
vival analysis such as recurrent events analysis
can be used. In general, longitudinal data are
richer and more informative and they can be
easy analyzed with modern software.
Next Steps in the SUNDIPS-Initiated Program
of Research
We are currently conducting a formal scoping
review of the literature on delirium in palliative
care settings, aiming to broadly provide a litera-
ture map of study designs, and thereby further
highlight evidence gaps. Formany of the individ-
ual questions in the analytical framework, we
plan to conduct systematic reviews. Although
the initial SUNDIPS meeting generated a broad
collaborative commitment, the specifics of
further collaboration in initial pilot and feasi-
bility studies will need to be addressed. These
include agreed commonality of study eligibility
criteria, assessment tools, diagnostic criteria,
outcome measures, and the pursuit of funding
opportunities. In addition, we acknowledge the
potential for selection bias in our small pilot sur-
vey of the SUNDIPS meeting participants.
Accordingly, we are planning to expand the sur-
vey to palliative care specialists at an interna-
tional level, aiming to assign a priority level to
the research questions and identify any addi-
tional areas of clinical equipoise and perceived
barriers tomulticenterobservational or interven-
tional study participation. The support of rele-
vant organizations such as the American
AcademyofHospiceandPalliativeMedicine,Na-
tional Hospice and Palliative CareOrganization,
American Delirium Society, European Delirium
Association and European Association for Pallia-
tive Care, the Palliative Care Clinical Studies
Collaborative in Australia, and All-Ireland Insti-
tute ofHospice and Palliative Carewill be sought
to promote research collaboration, knowledge
translation initiatives, and ultimately guideline
and policy development.Conclusions
Delirium in palliative care settings is charac-
terized by some remarkable clinical vagaries;not least its reversibility, even in advanced
illness; yet predicting the outcome of an
episode of delirium is often difficult. Delirium
is associated with personal and family distress,
poorer patient outcomes, health-care profes-
sional challenges, and greater health-care
costs. The projected demographic shift toward
an aging population will contribute to an
increased number of patients with dementia,
cancer-related deaths, and a high level of
comorbidity, making a compelling argument
to conduct further high-quality studies of
delirium in palliative care settings. Using an
analytical framework to represent the clinical
pathway of delirium in palliative care, we devel-
oped a series of research questions, broadly ad-
dressing epidemiology, including risk factor
evaluation; screening; diagnosis; pragmatic
management issues (pharmacologic and non-
pharmacologic); and development of predic-
tive models for delirium outcomes. Given
recruitment and attrition challenges in this
population, multicenter collaboration will
likely be a key solution. Ultimately, the knowl-
edge generated from better epidemiologic and
therapeutic interventional data will inform de-
cision making and policy development for
delirium detection and management and
thus help to achieve better outcomes for pa-
tients in palliative care settings.Disclosures and Acknowledgments
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